Latest Period
Q2 2026
Security Snapshot
Akebia Therapeutics, Inc. - COMMON STOCK (AKBA) Institutional Ownership
CUSIP: 00972D105
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
168
Shares (Excl. Options)
107,950,928
Price
$1.14
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- AKBA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 107,950,928
- Total 13F value
- $123,169,924
- Portfolio coverage rank
- 0%
- Share change
- +6,859,174
- Value change
- +$6,450,344
- Number of holders
- 168
- Shares outstanding
- 270,093,163
- SEC-reported price per share
- $1.35
- Insider filing price
- $1.35
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AKBA - Akebia Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 00972D105.
- 168 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 170 to 168 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $141,406,047 to $123,169,924.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 168 institutions filings for Q2 2026.
Security key
00972D105
Latest holder period
Q2 2026
13F holders
168
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
AKBA full holder history
Akebia Therapeutics, Inc. SEC filings
Akebia Therapeutics, Inc. company facts
Akebia Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00972D105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
AKBA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 7.2% | +18% | $30,943,909 | +$6,565,662 | 19,219,819 | +27% | BlackRock, Inc. | 31 Dec 2025 |
| STATE STREET CORP | 4.3% | -18% | $16,027,328 | -$2,861,506 | 11,614,006 | -15% | STATE STREET CORPORATION | 31 Mar 2026 |
| Satter Muneer A | 2.6% | $13,105,226 | 5,747,906 | Satter Muneer A | 31 Dec 2024 |
As of 30 Jun 2026, 168 institutional investors reported holding 107,950,928 shares of Akebia Therapeutics, Inc. - COMMON STOCK (AKBA). This represents 40% of the company’s total 270,093,163 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
34%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.4% | 19,986,374 | +6.9% | 0% | $22,784,466 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 11,322,143 | +1.4% | 0% | $12,907,243 |
| AQR CAPITAL MANAGEMENT LLC | 3.4% | 9,151,524 | +411% | 0% | $10,432,737 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.5% | 6,727,302 | +4.3% | 0% | $7,671,148 |
| STATE STREET CORP | 2% | 5,390,853 | -54% | 0% | $6,145,572 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1.6% | 4,273,026 | +894% | 0.02% | $4,871,250 |
| ACADIAN ASSET MANAGEMENT LLC | 1.5% | 4,004,867 | +191% | 0.01% | $4,559,000 |
| GOLDMAN SACHS GROUP INC | 1.4% | 3,689,167 | +2.4% | 0% | $4,205,650 |
| MILLENNIUM MANAGEMENT LLC | 1.2% | 3,196,605 | +34% | 0% | $3,644,130 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.94% | 2,533,977 | +14% | 0% | $2,888,734 |
| TWO SIGMA INVESTMENTS, LP | 0.9% | 2,436,673 | +88% | 0% | $2,777,807 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.85% | 2,300,438 | +14% | 0% | $2,622,499 |
| NORTHERN TRUST CORP | 0.8% | 2,160,365 | +11% | 0% | $2,462,816 |
| Nantahala Capital Management, LLC | 0.74% | 2,000,000 | 0% | 0.14% | $2,280,000 |
| VANGUARD FIDUCIARY TRUST CO | 0.71% | 1,908,797 | +7.3% | 0% | $2,176,029 |
| FMR LLC | 0.69% | 1,871,059 | +40% | 0% | $2,133,008 |
| Qube Research & Technologies Ltd | 0.66% | 1,779,707 | -26% | 0% | $2,028,866 |
| CITADEL ADVISORS LLC | 0.64% | 1,717,659 | +24% | 0% | $1,958,131 |
| UBS Group AG | 0.51% | 1,374,950 | +79% | 0% | $1,567,442 |
| RENAISSANCE TECHNOLOGIES LLC | 0.45% | 1,223,963 | -33% | 0% | $1,395,318 |
| CITIGROUP INC | 0.42% | 1,124,570 | -61% | 0% | $1,282,010 |
| Hennion & Walsh Asset Management, Inc. | 0.31% | 839,729 | +33% | 0.03% | $957,291 |
| MORGAN STANLEY | 0.26% | 701,540 | +21% | 0% | $799,756 |
| Invesco Ltd. | 0.26% | 694,928 | -3.5% | 0% | $792,218 |
| MANGROVE PARTNERS IM, LLC | 0.25% | 666,954 | +77% | 0.05% | $760,328 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 107,950,928 | $123,169,924 | +$6,450,344 | $1.14 | 168 |
| 2026 Q1 | 101,697,319 | $141,406,047 | -$23,299,678 | $1.39 | 170 |
| 2025 Q4 | 118,251,483 | $190,384,320 | -$16,096,783 | $1.61 | 165 |
| 2025 Q3 | 123,669,076 | $337,684,321 | +$36,363,104 | $2.73 | 176 |
| 2025 Q2 | 108,291,108 | $394,183,978 | +$56,486,637 | $3.64 | 157 |
| 2025 Q1 | 95,246,755 | $182,865,666 | +$63,362,812 | $1.92 | 142 |
| 2024 Q4 | 67,845,406 | $128,903,910 | +$16,367,542 | $1.90 | 120 |
| 2024 Q3 | 59,433,206 | $78,446,645 | +$886,944 | $1.32 | 113 |
| 2024 Q2 | 56,272,261 | $57,424,732 | -$2,482,254 | $1.02 | 100 |
| 2024 Q1 | 56,991,509 | $104,293,412 | +$2,027,480 | $1.83 | 108 |
| 2023 Q4 | 54,644,403 | $67,756,919 | +$4,503,736 | $1.24 | 83 |
| 2023 Q3 | 50,796,845 | $57,906,145 | +$685,292 | $1.14 | 72 |
| 2023 Q2 | 50,244,290 | $45,972,433 | -$1,392,343 | $0.92 | 76 |
| 2023 Q1 | 51,839,170 | $29,049,633 | -$98,488 | $0.56 | 62 |
| 2022 Q4 | 52,253,997 | $30,149,698 | +$763,514 | $0.58 | 70 |
| 2022 Q3 | 52,161,214 | $16,491,885 | -$1,812,681 | $0.32 | 79 |
| 2022 Q2 | 57,164,176 | $20,180,226 | -$11,164,741 | $0.35 | 82 |
| 2022 Q1 | 81,183,875 | $58,271,372 | -$32,826,439 | $0.72 | 115 |
| 2021 Q4 | 96,816,883 | $218,731,670 | -$6,193,557 | $2.26 | 128 |
| 2021 Q3 | 98,493,468 | $283,669,170 | -$32,502,791 | $2.88 | 119 |
| 2021 Q2 | 106,173,637 | $402,396,029 | +$22,237,368 | $3.79 | 131 |
| 2021 Q1 | 100,546,584 | $340,303,134 | -$8,611,368 | $3.38 | 134 |
| 2020 Q4 | 103,249,738 | $289,096,531 | -$2,381,228 | $2.80 | 134 |
| 2020 Q3 | 100,173,386 | $251,381,270 | -$415,118,712 | $2.51 | 155 |
| 2020 Q2 | 111,597,128 | $1,515,160,970 | +$263,628,807 | $13.58 | 184 |